5,480 Shares in AbbVie Inc. $ABBV Purchased by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,480 shares of the company’s stock, valued at approximately $1,269,000.

Other large investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB boosted its position in shares of AbbVie by 0.7% in the third quarter. Wilmington Savings Fund Society FSB now owns 78,338 shares of the company’s stock worth $18,138,000 after buying an additional 538 shares during the period. BXM Wealth LLC lifted its stake in AbbVie by 34.5% in the 3rd quarter. BXM Wealth LLC now owns 4,950 shares of the company’s stock worth $1,146,000 after acquiring an additional 1,269 shares in the last quarter. Foundation Wealth Management LLC acquired a new stake in AbbVie during the 3rd quarter worth about $209,000. OVERSEA CHINESE BANKING Corp Ltd grew its stake in AbbVie by 56.6% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 2,962 shares of the company’s stock valued at $686,000 after acquiring an additional 1,070 shares in the last quarter. Finally, Balanced Wealth Group LLC grew its stake in AbbVie by 3.9% during the 3rd quarter. Balanced Wealth Group LLC now owns 3,749 shares of the company’s stock valued at $868,000 after acquiring an additional 140 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $214.38 on Monday. The business’s 50-day simple moving average is $226.80 and its 200-day simple moving average is $216.65. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a market cap of $378.89 billion, a price-to-earnings ratio of 162.41, a P/E/G ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the prior year, the business earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

Analyst Ratings Changes

ABBV has been the subject of several research reports. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Bank of America boosted their price target on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Piper Sandler reiterated an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.